Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Treatment with monoclonal antibody specific for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective therapy for the treatment of metastatic melanoma. Although subject to debate, current models favor a mechanism of activity involving blockade of the inhibitory activity of CTLA-4 on both effector (T eff) and regulatory (T reg) T cells, resulting in enhanced antitumor effector T cell activity capable of inducing tumor regression. We demonstrate, however, that the activity of anti-CTLA-4 antibody on the T reg cell compartment is mediated via selective depletion of T reg cells within tumor lesions. Importantly, T reg cell depletion is dependent on the presence of Fcγ receptor-expressing macrophages within the tumor microenvironment, indicating that T reg cells are depleted in trans in a context-dependent manner. Our results reveal further mechanistic insight into the activity of anti-CTLA-4-based cancer immunotherapy, and illustrate the importance of specific features of the local tumor environment on the final outcome of antibody-based immunomodulatory therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, multiple studies have been confirmed that antibody-dependent cell-mediated cytotoxicity of Treg also substantially contributes to the antitumor activity of ipilimumab [128–130].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [129]
Experimental — accuracy not yet measuredIn the citing paper
“CTLA-4 is also expressed on Tregs; targeting CTLA-4 could theoretically lead to Treg cell dysfunction or depletion as has been demonstrated in mice (Simpson et al., 2013), though not all data support this notion in humans”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 6×
“The lack of additive or synergistic therapeutic benefit of the combination of –CTLA-4 with peptide vaccination in the recent phase III clinical trial (Hodi et al., 2010) could at least be partially explained by a lack of vaccine-mediated impact on appropriate accessory cell populations.”
BackgroundInfluentialSelf-citationFoxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
BackgroundIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 1×
“–CTLA-4 therapy has demonstrated significant antitumor activity in preclinical tumor models (Leach et al., 1996; van Elsas et al., 1999; Quezada et al., 2011) and in clinical trials as an immunotherapy for metastatic melanoma (Hodi et al., 2010; Robert et al., 2011).”
BackgroundSelf-citationCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 2×
“, 2001), the demonstration that CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et a…”
BackgroundFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 14×
“In mice, ADCC is regulated predominantly by the low-affinity receptors FcRIII and FcRIV (Nimmerjahn et al., 2005; Nimmerjahn et al., 2010; Setiady et al., 2010), and to a lesser extent by the highaffinity FcRI (Fossati-Jimack et al., 2000; Tedder et al., 2006; Hamaguchi et al., 2006).”
BackgroundInfluentialSelf-citationTakahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · cited 1×
“…CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et al., 2008).”
BackgroundRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice
Kim, J. M., Rasmussen, J. P., & Rudensky, A. Y. (2007) · Nature Immunology · doi:10.1038/ni1428 · Cited by 1,820 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
Background
Cited by
Items 801–900 of 1,000
Chemokine biology on immune checkpoint–targeted therapies
Letourneur, D., Danlos, F., & Marabelle, A. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.009 · Cited by 29
Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions
Zeng, G., Jin, L., Ying, Q., Chen, H., Thembinkosi, M. C., Yang, C., Zhao, J., Ji, H., Lin, S., Peng, R., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s265828 · Cited by 28
Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 32
The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives
Sancho‐Araiz, A., Sanjuan, V. M., & Trocóniz, I. F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071016 · Cited by 30
“The tumor microenvironment (TME) comprises a heterogeneous population of cancer cells, as well as a variety of resident and infiltrating host cells, secreted factors and extracellular matrix proteins.”
BackgroundImmune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers
Zhou, G., Boor, P. P. C., Bruno, M. J., Sprengers, D., & Kwekkeboom, J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01453-3 · Cited by 33
“blockade of LAG3 and PD-L1 additively enhanced the effects.(8,55) Many clinical trials studying LAG3 blockade as a monotherapy or in combination with anti-PD-1 antibodies are currently ongoing in patients with diverse types of cancer.”
BackgroundSantinon, F., Bennani, F. E., Bachais, M., Pacis, A., & Rudd, C. E. (2022) · Scientific Reports · doi:10.1038/s41598-022-23016-z · Cited by 27
Stater, E. P., Morcos, G., Isaac, E. L., Ogirala, A., Hsu, H., Longo, V. A., & Grimm, J. (2023) · ACS Nano · doi:10.1021/acsnano.2c05800 · Cited by 26
Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy
Ryba-Stanisławowska, M. E. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00992-0 · Cited by 26
The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy
Kim, H. J., & Cantor, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0153 · Cited by 29
“(ADCC), resulting in an increase in the Teff:Treg ratio (91, 92, 97).”
BackgroundInfluentialLi, B., Xu, L., Tao, F., Xie, K., Wu, Z., Li, Y., Li, J., Chen, K., Pi, C., Mendelsohn, A. R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17000 · Cited by 26
A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects
Yang, F., Zhao, L., Wei, Z., Yang, Y., Liu, J., Li, Y., Tian, X., Liu, X., Lü, X., & Sui, J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901413 · Cited by 27
Polesso, F., Munks, M. W., Rott, K. H., Smart, S. M., Hill, A. B., & Moran, A. E. (2021) · European Journal of Immunology · doi:10.1002/eji.202048960 · Cited by 27
“For example, anti-PD-1 clones G4 and J43 are hamster IgG, the same species and isotype as anti-CTLA-4 clones 9H10 and 4F10, which are known to deplete Treg TILs in vivo (Simpson et al., 2013).”
BackgroundAnti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy
Pol, J. G., & Kroemer, G. (2018) · Cell Research · doi:10.1038/s41422-018-0031-9 · Cited by 28
Understanding and overcoming resistance to immunotherapy in genitourinary cancers
Evans, S. T., Jani, Y. C., Jansen, C. S., Yıldırım, A., Kalemoglu, E., & Bilen, M. A. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2342599 · Cited by 26
“97 An increased Teff-to-Treg ratio has been correlated with improved responses to these treatments.”
BackgroundT cell-mediated mechanisms of immune-related adverse events induced by immune checkpoint inhibitors
Li, L., Huang, Y., Xue, R., Li, L., Li, L., Liang, L., Lai, K., Huang, X., Qin, Y., & Zheng, Y. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104808 · Cited by 28
Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy
Liu, X., Gall, C. M. L., Alexander, R., Borgman, E., Balligand, T., & Ploegh, H. L. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01447-z · Cited by 26
“For anti-CTLA-4 immunotherapy, both receptor blockade and FcR engagement contribute to its efficacy 12–17 .”
Dahal, L. N., Huang, C.-Y., Stopforth, R. J., Mead, A., Chan, K., Bowater, J. X., Taylor, M. C., Narang, P., Chan, H. T. C., Kim, J. H., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701122 · Cited by 25
“A requirement for macrophages was similarly reported in the context of anti-CD30 (12) and anti-CD40 (13) Ab therapy in mouse lymphoma models and recently in checkpoint blockade therapy, such as anti-CTLA-4 (14) and anti–PD-L1 (15), against melanoma in murine models.”
BackgroundTipping the balance: inhibitory checkpoints in intestinal homeostasis
Joosse, M. E., Nederlof, I., Walker, L. S. K., & Samsom, J. N. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0113-5 · Cited by 26
Opportunities and challenges of bi-specific antibodies
Segués, A., Huang, S., Sijts, A. J. A. M., Berraondo, P., & Zaiss, D. M. W. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.05.001 · Cited by 25
New Immuno-oncology Targets and Resistance Mechanisms
Tokaz, M. C., Baik, C. S., Houghton, A. M., & Tseng, D. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01005-8 · Cited by 26
Wei, X. L., Zhao, L., Yang, F., Yang, Y., Zhang, H., Du, K., Tian, X., Fan, R., Si, G., Wang, K., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.010 · Cited by 26
“77 We also found that CD25 (cid:1) TIGIT bsAbs combine an Fc-mediated depletive capacity and a Fab-mediated blocking capacity in the same molecule.”
Pharmacological Modulation of Proton Channel Hv1 in Cancer Therapy: Future Perspectives
Fernández, A., Pupo, A., Mena‐Ulecia, K., & Gonzalez, C. L. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.103804 · Cited by 26
“These results, together with preclinical experiments (Bulliard et al., 2013; Selby et al., 2013; Simpson et al., 2013), show that antitumor activity of anti-CTLA-4 antibodies could be attributed, at least partially, to the depletion of Tregs.”
ResultRathinasamy, A., Domschke, C., Ge, Y., Böhm, H.-H., Dettling, S., Jansen, D., Lasitschka, F., Umansky, L., Gräler, M. H., Hartmann, J., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1964-4 · Cited by 25
“Infiltration of Treg into tumors is associated with enhanced tumor growth and poor prognosis [1–3] and their therapeutic depletion through antibody-dependent cell-mediated cytotoxicity (ADCC)-proficient antibodies against a Treg-associated molecule CTLA-4 or low-dose cyclophosphamide treatment can improve anti-tumor T…”
BackgroundMarei, H. E. S., Al-Thani, A., Caceci, T., Arriga, R., Sconocchia, T., Ottaviani, A., Lanzilli, G., Roselli, M., Caratelli, S., Cenciarelli, C., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.06.002 · Cited by 28
Cui, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.573547 · Cited by 29
“Zhang et al. (54) have immunohistochemically shown that the TIME of dMMR/MSI-H CRCs differs from that of pMMR/MSI-L CRCs.”
BackgroundInfluentialMokhtari, R. B., Sambi, M., Qorri, B., Baluch, N., Ashayeri, N., Kumar, S., Cheng, H. M., Yeger, H., Das, B., & Szewczuk, M. R. (2021) · Cancers · doi:10.3390/cancers13143596 · Cited by 27
“For example, some anti-CTLA-4 antibodies have been shown to decrease regulatory T cells and inhibit checkpoint functionality [44,45].”
BackgroundLi, G., Li, S., Jiang, Y., Chen, T., & An, Z. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113952 · Cited by 25
The dual role of IgG4 in immunity: bridging pathophysiology and therapeutic applications
Piseddu, I., Mayerle, J. V., Mahajan, U. M., & Boehmer, D. F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335375 · Cited by 25
Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond
Dallos, M. C., & Drake, C. G. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000302 · Cited by 25
“This strategy is potentially synergistic, given that blocking CTLA-4 may predominantly inhibit Tregs, whereas inhibition of PD-1 activates cytotoxic T cells.(62,63) In a recently published phase Ib study (CheckMate 016), patients with mRCC received different dose combinations of nivolumab plus ipilimumab.”
BackgroundCTLA-4 Immunohistochemistry and Quantitative Image Analysis for Profiling of Human Cancers
Brown, C., Sekhavati, F., Cárdenes, R., Windmueller, C., Dacosta, K., Rodriguez‐Canales, J., & Steele, K. E. (2019) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155419882292 · Cited by 26
Ryan, J. M., Wasser, J. S., Adler, A. J., & Vella, A. T. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1152256 · Cited by 24
Miguel, A., Sendra, L., Noé, V., Ciudad, C. J., Dasí, F., Hervás, D., Herrero, M. J., & Aliño, S. F. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s104393 · Cited by 24
“Recently, a study showed Treg depletion observed in the tumor infiltrate after anti-CTLA4 therapy to be mainly mediated by antibody-dependent cell cytotoxicity.(47) In our study, treatment with anti-CTLA4 2′-OMe-PS-ASO blocked CTLA4 expression, but this did not deplete Treg cells – thus indicating that they can also m…”
Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma
Moskovitz, J. M., & Ferris, R. L. (2018) · Journal of Dental Research · doi:10.1177/0022034518759464 · Cited by 26
“Preclinical studies with CTLA4 knockout mice demonstrated profound autoimmunity resulting in death; however, CTLA4 blockade demonstrated a surprising effect: tumor regression without overt immune toxicities (Peggs et al. 2009; Simpson et al. 2013; Sandin et al. 2014; Pedros et al. 2017).”
BackgroundZhou, X., Zhao, S., He, Y., Geng, S., Shi, Y., & Wang, B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1250 · Cited by 24
Burlion, A., Ramos, R. N., Pukar, K. C., Sendeyo, K., Corneau, A., Ménétrier‐Caux, C., Piaggio, E., Olive, D., Caux, C., & Marodon, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596005 · Cited by 26
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies
Golay, J., & Andrea, A. E. (2020) · Antibodies · doi:10.3390/antib9020017 · Cited by 25
“Perhaps the most studied example of the effect of isotype on efficacy is that the anti-CTLA-4 IgG1 isotype may be preferred over IgG4 or IgG2, because one possible mechanism of anti-CTLA-4 antibody activity is the killing of Tregs [23,51,128].”
BackgroundUnderstanding and Overcoming the Inflammatory Toxicities of Immunotherapy
Dougan, M. L. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0372 · Cited by 26
“Animal studies have demonstrated a role for Fc-dependent Treg depletion in the antitumormechanism of CTLA-4–targeting antibodies (15, 16).”
BackgroundDahl, O., & Brydøy, M. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1555375 · Cited by 24
“Antibodies against CTLA-4 can also deplete immunosuppressive CD4 T-cells (regulatory T-cells) [43,44].”
BackgroundImmune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence
Eshaq, A. M., Flanagan, T. W., Abbad, A. A. B., Makarem, Z. A. A., Bokir, M. S., Alasheq, A. K., Asheikh, S. A. A., Almashhor, A. M., Binyamani, F., Al-Amoudi, W. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010088 · Cited by 23
Therapeutic Combinations of Immune-Modulating Antibodies in Melanoma and Beyond
Cohen, J. V., & Sznol, M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.014 · Cited by 23
“antibody-dependent cell-mediated cytotoxicity (ADCC), which may contribute to the synergistic anti-tumor effects observed in combination with PD-1/PD-L1 antagonists.(26,27) A subset of Treg and Th2 CD4+ T cells have been shown to express CC chemokine receptor 4 (CCR4).”
BackgroundLal, J. C., Townsend, M. G., Mehta, A. K., Oliwa, M., Miller, E., Sotayo, A. O., Cheney, E. M., Mittendorf, E. A., Letai, A. G., & Guerriero, J. L. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01448-1 · Cited by 24
Liu, J., Wang, X., Deng, Y., Yu, X., Wang, H., & Li, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.766248 · Cited by 27
Hu, Y. Y., Paris, S., Bertolet, G., Barsoumian, H. B., Wang, Q., SILVA, J. D., Patel, N. B., Nguyen, N., Doss, D. J., Huang, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1022011 · Cited by 23
“As CTLA4 is predominately expressed by T regulatory cells (Tregs), this results in the preferential depletion of this immunosuppressive cell population (10, 11).”
BackgroundAndresen, N. K., Røssevold, A. H., Quaghebeur, C., Gilje, B., Boge, B., Gombos, A., Falk, R. S., Mathiesen, R. R., Julsrud, L., Garred, Ø., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007990 · Cited by 23
Huang, Y., Chen, Z., Shen, G., Fang, S., Zheng, J., Chi, Z., Zhang, Y., Zou, Y., Gan, Q., Liao, C., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2318815 · Cited by 24
Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists
Callahan, M. K., & Wolchok, J. D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.008 · Cited by 23
Self-citationField, C. S., Hunn, M. K., Ferguson, P. M., Ruedl, C., Ancelet, L. R., & Hermans, I. F. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1376154 · Cited by 25
“This is notable because depletion of Tregs in the tumor environment has received recent attention as a potential mode of activity of a-CTLA-4 therapy.(12) The preferential accumulation of CD4C T cells in the tumor may reflect privileged access to the CNS due to expression of integrins important for transport across th…”
BackgroundRole of FcγRs in Antibody-Based Cancer Therapy
Graziano, R. F., & Engelhardt, J. (2019) · Current topics in microbiology and immunology · doi:10.1007/82_2019_150 · Cited by 26
Regulatory T cells in cancer: where are we now?
Gallimore, A., Quezada, S. A., & Roychoudhuri, R. (2019) · Immunology · doi:10.1111/imm.13088 · Cited by 24
Self-citationPhase I trials in oncology: a new era has started
Postel-Vinay, S. C., & Soria, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu513 · Cited by 23
Qi, H., Sun, Z., Gao, T., Yao, Y., Yu, W., Li, W., Wang, X., Wang, X., Liu, D., & Jiang, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01958-4 · Cited by 22
Singh, B. H., & Gulley, J. L. (2014) · Therapeutic Advances in Vaccines · doi:10.1177/2051013614539478 · Cited by 22
Liu, X., Chen, J., Lu, W., Zeng, Z., Li, J., Jiang, X., Gao, Y., Gong, Y. Q., Wu, Q., & Xie, C. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.576566 · Cited by 25
Evaluating the impacts of emerging cancer therapies on ovarian function
Alesi, L. R., Winship, A., & Hutt, K. J. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.12.004 · Cited by 22
Metabolism heterogeneity in melanoma fuels deactivation of immunotherapy: Predict before protect
Zhang, X., Tai, Z., Miao, F., Huang, H., Zhu, Q., Bao, L., & Chen, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1046102 · Cited by 25
Fujikawa, K., Saito, T., Kurose, K., Kojima, T., Funakoshi, T., Sato, E., Kakimi, K., Iida, S., Doki, Y., Oka, M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291772 · Cited by 23
Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer
Ni, R., Hu, Z., & Tao, R. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117430 · Cited by 23
Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity
Gu, Y., Fan, C., Lu, R., Shao, B., Sang, Y., Huang, Q., Li, X., Meng, W., Mo, X., & Wei, Y.-Q. (2016) · Scientific Reports · doi:10.1038/srep32351 · Cited by 22
Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults
Elias, R., Morales, J. K., & Presley, C. J. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0619-0 · Cited by 22
Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges
Tremble, L. F., Forde, P. F., & Soden, D. M. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2065-0 · Cited by 23
Lamichhane, P., Amin, N. P., Agarwal, M., & Lamichhane, N. (2018) · Medicines · doi:10.3390/medicines5040114 · Cited by 22
“While CTLA-4 blockade has been shown to selectively deplete Tregs in a Fc-Fcγ-dependent manner in mouse models [38], it is unable to deplete Tregs in human cancers [39], highlighting the need and potential for modifications of Fc portions for enhanced Fc-mediated depletion of Tregs.”
BackgroundMathew, D., & Torres, R. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.531910 · Cited by 24
“Of note, recent data has suggested that an alternate mechanism by which anti-CTLA4 antibodies act is via the depletion of regulatory T cells (15, 16), thus questioning its mechanism of action as a checkpoint blockade therapy and suggesting it may instead act as an antibody depleting therapy.”
Backgrounddos Santos, L. I., Galvão-Filho, B., de Faria, P. C., Junqueira, C., Dutra, M. S., Teixeira, S. M. R., Rodrigues, M. M., Ritter, G., Bannard, O., Fearon, D. T., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1634-8 · Cited by 23
“It is worth mentioning that anti-CTLA-4 depletes Tregs when this cell subpopulation is assessed 1 or 2 days after treatment [26, 29].”
BackgroundResultHow does the gut microbiome influence immune checkpoint blockade therapy?
Almonte, A. A., Rangarajan, H., Yip, D., & Fahrer, A. M. (2021) · Immunology & Cell Biology · doi:10.1111/imcb.12423 · Cited by 21
“Anti-CTLA-4 requires a competent Fc region in order to provide optimal therapeutic benefit.(23,24) Furthermore, different isotypes of anti-CTLA4 have different therapeutic efficacies, with IgG2a being the most potent for anticancer therapy.”
BackgroundWang, C., Yang, M., Zhong, Y., Cao, K., Wang, X., Zhang, C., Wang, Y., He, M., Lu, J., Zhang, G., et al. (2025) · 癌症:英文版 · doi:10.1002/cac2.70021 · Cited by 23
Cytotoxic IgG: Mechanisms, functions, and applications
Wöhner, M., & Nimmerjahn, F. (2025) · Immunity · doi:10.1016/j.immuni.2025.05.008 · Cited by 22
Damei, I., Caidi, A., Auclin, É., Adam, J., Mella, S., Hasan, M., Tartour, É., Robert, C., Corgnac, S., & Mami‐Chouaib, F. (2025) · Nature Communications · doi:10.1038/s41467-025-60657-w · Cited by 24
“…and a selective depletion of Treg cells in the tumour microenvironment and the destabilization of tumour-in fi ltrating Treg cells play a key role in the ef fi cacy of CTLA-4 blockade therapy in melanoma 42 and are correlated with tumour-speci fi c CD8 T-cell responses in anti-CTLA-4-treated mice 43 .”
Hernandez, C., Thomas‐Chollier, M., Naldi, A., & Thieffry, D. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.558606 · Cited by 23
Cho, O., Lee, J.-W., Kim, H., Jeong, Y.-J., & Heo, T. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121559 · Cited by 22
Abenavoli, L., Montori, M., Svegliati‐Baroni, G., Argenziano, M. E., Giorgi, F., Scarlata, G. G. M., Ponziani, F. R., & Scarpellini, E. (2023) · Medicina · doi:10.3390/medicina59081427 · Cited by 23
“, TIM-3, LAG-3, TIGIT, VISTA and BTLA) [82] - Decreased TILs to Treg ratio [83,84] - Down-regulation of dendritic cell recruitment through b-catenin signaling [85] - Increased immunosuppressive cells expression (e.”
BackgroundAnalysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor
Xu, J., Chen, G., Yu, S., Yao, S., Li, W., & Cheng, H. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.10.011 · Cited by 21
Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer
Jama, M., Tabana, Y., & Barakat, K. (2024) · European journal of medical research · doi:10.1186/s40001-024-01901-9 · Cited by 23
“1) [8, 11, 13, 18, 49, 55, 94, 97, 108].”
Han, L., Wang, W., Lu, J., Kong, F., Ma, G., Zhu, Y., Zhao, D., Zhu, J., Shuai, W., Zhou, Q., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.006 · Cited by 22
Self-citationImmunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer
Niyongere, S., Saltos, A. N., & Gray, J. E. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.120 · Cited by 21
Kyriazis, P. P., Tiwary, A. K., Freeman, J., Landry, D. L., & Braden, G. L. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-02766-w · Cited by 23
Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
Hao, Y., & Cook, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.806043 · Cited by 23
“studies have shown FcR binding results in Treg depletion by interaction with tumour-infiltrating myeloid cells, which is crucial for their anti-tumour effects (56, 57).”
BackgroundWang, C. J., Petersone, L., Edner, N. M., Heuts, F. W. H., Ovcinnikovs, V., Ntavli, E., Kogimtzis, A., Fabri, A., Elfaki, Y., Houghton, L. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34477-1 · Cited by 22
Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects
Hwang, I., & Nguyen, N. T. M. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0566-y · Cited by 21
“It is postulated that the CTLA-4–mAb lowers the threshold level of TCR signaling for T cell activation to disrupt a mechanism of peripheral T cell tolerance (Simpson et al. 2013).”
BackgroundToxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody
Gombos, R. B., Gonzalez, A., Manrique, M. L., Chand, D. S., Savitsky, D. A., Morin, B. M., Breous-Nystrom, E., Dupont, C. D., Ward, R., Mundt, C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191926 · Cited by 21
Self-citationZhang, Z., Zhang, L., Wang, K., Xie, T., Zhang, X., Yu, W., Li, Y., Shen, L., Li, R., & Peng, Z. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00715-6 · Cited by 24
Jiang, X., Rudqvist, N.-P., Jiang, B., Ye, S., He, S., Liang, Q., Dou, J., Williams, M. D., Dunn, J. D., Johnson, J. M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1390 · Cited by 23
“Collectively, our data are consistent with a hypothesis of eTreg depletion by highly cytotoxic FCGR3A + NK cells via ipilimumab-induced ADCC.”
InfluentialKlyushnenkova, E., Riabov, V., Kouiavskaia, D. V., Wietsma, A. C., Zhan, M., & Alexander, R. B. (2014) · The Prostate · doi:10.1002/pros.22858 · Cited by 21
“This observation contrasted with a recent report that antiCTLA-4 mAb treatment may deplete tumor-infiltrating Tregs in Fc-dependent manner [14].”
BackgroundMethodResultEffect of pembrolizumab on CD4+CD25+, CD4+LAP+ and CD4+TIM-3+ T cell subsets
Toor, S. M., Nair, V. S., Pfister, G., & Elkord, E. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13264 · Cited by 20
Blair, T. C., Baird, J. R., Bambina, S., Kramer, G. F., Gostissa, M., Harvey, C. J., Gough, M. J., & Crittenden, M. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-19256-8 · Cited by 20
Santiago-Sánchez, G. S., Hodge, J. W., & Fabian, K. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993624 · Cited by 21
“In a follow-up study, it was elucidated that the activity of anti-CTLA-4 is mediated via selective Treg depletion within the tumor site (32).”
BackgroundImmune checkpoint activity regulates polycystic kidney disease progression
Kleczko, E. K., Nguyen, D. T., Marsh, K. H., Bauer, C. D., Li, A. S., Monaghan, M. T., Berger, M. D., Furgeson, S. B., Gitomer, B. Y., Chonchol, M. B., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.161318 · Cited by 21
“Correlatively, recent cancer studies have shown that treatment with anti-CTLA-4 results in a reduction of intratumoral TRegs, representing a noncanonical mechanism that may contribute to therapeutic efficacy(55-57).”
BackgroundImmune‐related adverse events of antibody‐based biological medicines in cancer therapy
Rajagopal, D., MacLeod, E., Corogeanu, D., & Vessillier, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18470 · Cited by 22
Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis
Arriola, E., Wheater, M. J., Lopez, M. A., Thomas, G. J., & Ottensmeier, C. H. H. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1209615 · Cited by 21
Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model
Rakhmilevich, A. L., Felder, M. A. R., Lever, L., Slowinski, J., Rasmussen, K., Hoefges, A., Voort, T. J. V. D., Loibner, H., Korman, A. J., Gillies, S. D., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601255 · Cited by 20
“The mechanisms of anti– CTLA-4 augmenting T cell responses have been shown by others to be related to the blockade of the inhibitory activity of CTLA-4 on effector T cells (17, 18) and also to the depletion of CD4 Tregs (46, 48), particularly for the anti–CTLA-4 IgG2a isotype.”
Synergistic combination of oncolytic virotherapy with CAR T-cell therapy
Ajina, A., & Maher, J. F. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.015 · Cited by 21
Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors
Davar, D., & Zarour, H. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_2 · Cited by 22
Li, D., Li, J., Chu, H., & Wang, Z. (2020) · mAbs · doi:10.1080/19420862.2020.1725365 · Cited by 20
“This observation is consistent with recent studies showing that the anti-tumor efficacy of an anti-mCTLA-4 antibody with hamster IgG2 isotype was also mediated largely by ADCC effects on Tregs.(5) 7 8 The two anti-CTLA-4 antibodies, ipilimumab and tremelimumab, have similar binding properties,(16) whereas mAb146 has u…”
ResultNebot-Bral, L., Hollebecque, A., Yurchenko, A. A., Forceville, L. D., Danjou, M., Jouniaux, J.-M., Rosa, R. C. A., Pouvelle, C., Aoufouchi, S., Vuagnat, P., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005059 · Cited by 20
Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy
Fekrirad, Z., Behrooz, A. B., Ghaemi, S., Khosrojerdi, A., Zarepour, A., Zarrabi, A., Arefian, E., & Ghavami, S. (2022) · Cancers · doi:10.3390/cancers14153698 · Cited by 22
“Research suggests that blocking the CTLA-4 inhibitory signal that leads to the reduction in Treg cells at tumor locations is critical for CTLA-4 mAb-mediated anticancer activity [22].”
BackgroundAdvancements in melanoma cancer metastasis models
Melo, L. M. N., Kumar, S., Riess, V., Szylo, K. J., Eisenburger, R. T., Schadendorf, D., Ubellacker, J. M., & Tasdogan, A. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13078 · Cited by 24
“…CTLA- 4 antibody, GM- CSF vaccine, and combinatory treatments In vitro assays and in vivo tumor model of B16/BL6 melanoma Peggs et al. (2009), Simpson et al. (2013) Anti- PD- 1 and anti- CTLA- 4 antibodies and combinatory treatments In vivo tumor model of B16/BL6 melanoma Spranger et al.…”
BackgroundWaight, J. D., Gombos, R. B., & Wilson, N. S. (2017) · Human Antibodies · doi:10.3233/hab-160308 · Cited by 23
“Consistent with this approach, surrogate antibodies targeting mouse CD357 and CD134 showed superior anti-tumor activity when the antibody Fc region effectively co-engaged activating Fc γ Rs [19,20, 151,157].”
Schuurman, J., & Parren, P. W. H. I. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.04.001 · Cited by 20
CTLA-4—two pathways to anti-tumour immunity?
Ward, F. J., Kennedy, P. T., Al-Fatyan, F., Dahal, L. N., & Eid, R. A. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltaf008 · Cited by 22
“The antibody Fc domain is, therefore, critical to their anti-tumour function, because reformatting antibodies onto a benign sub-class or Fc silent background, completely abolishes their efficacy [63–66, 68 –71 ].”
Zhang, T., Gu, F., Lin, W., Shao, H., Jiang, A., & Guan, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1611299 · Cited by 24
“CTLA-4 blockade can deplete the Treg cells from the tumor microenvironment and facilitate a paradigm shift in immunotherapy (20).”
A next-generation anti-CTLA-4 probody mitigates toxicity and enhances anti-tumor immunity in mice
Cao, W., Chen, J., Fu, Y., Jiang, H., Gao, Y., Huang, H., Fu, Y., & Wang, W. (2025) · Nature Communications · doi:10.1038/s41467-025-64081-y · Cited by 20
Metadata
- Authors
- Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., Peggs, K. S., Ravetch, J. V., Allison, J. P., & Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Rockefeller University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 3
- University College London (GB)
- Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK 6
- Department of Immunology, Juntendo University School of Medicine, 113-8421 Tokyo, Japan 5
- Corresponding author
- Allison, James P.
- Quezada, Sergio A.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-07-29
- Volume
- 210
- Issue
- 9
- Pages
- 1695-1710
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3754863
- OpenAlex
- W2121080857
- Cited by
- 1,472
- References
- 60
- Citations by year
- 2026: 66 · 2025: 79 · 2024: 97 · 2023: 89 · 2022: 112 · 2021: 140 · 2020: 158 · 2019: 125 · 2018: 122 · 2017: 126 · 2016: 121 · 2015: 135 · 2014: 85 · 2013: 15
- FWCI
- 63.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research UK (12100)
- Canadian Institutes of Health Research
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, CTLA-4, regulatory T cells, melanoma, Fc gamma receptor, tumor-infiltrating macrophages, T cell depletion, tumor microenvironment, cancer immunotherapy, metastatic melanoma
- MeSH terms
- Animals, Cell Membrane, Clone Cells, Lymph Nodes, Lymphocyte Depletion, Melanoma, Mice, Inbred C57BL, Phagocytes, Signal Transduction, CD4 Antigens, Granulocyte-Macrophage Colony-Stimulating Factor, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Receptors, IgG, CD8-Positive T-Lymphocytes, Lymphocyte Count, Antibodies, Blocking, CD11b Antigen, T-Lymphocytes, Regulatory, Mice, TNF-Related Apoptosis-Inducing Ligand, Fas Ligand Protein, Tumor Microenvironment, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.